In fasciitis patients with a known underlying truncating NFKB1 mutation, anti-inflammatory therapies, including glucocorticoids and/or IL-1β targeting therapies or JAK inhibitors, could be beneficial in reducing excessive inflammation and the need for surgical revisions and amputations. This evidence concerns the gene IL1B and fasciitis.